Results 161 to 170 of about 368,095 (294)

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Corrigendum to "Exosomes as novel tools for renal cell carcinoma therapy, diagnosis, and prognosis" [Heliyon Volume 10, Issue 12, June 30, 2024, Article e32875]. [PDF]

Heliyon
Razavinia A, Razavinia A, Jamshidi Khalife Lou R, Ghavami M, Shahri F, Tafazoli A, Khalesi B, Hashemi ZS, Khalili S.   +8 more
europepmc   +1 more source

GSBS News, Winter 2008 [PDF]

, 2008
Graduate School of Biomedical Sciences, University of Texas Health Science Center at Houston/M.D. Anderson Cancer Center
core   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Monitoring Multi-Drug Resistant Klebsiella pneumoniae in Kitagata Hot Spring, Southwestern Uganda: A Public Health Implication

Infection and Drug Resistance
Kaltume Umar Hambali,1 Emmanuel Eilu,1 Sunil Kumar,1 Abdullateef Opeyemi Afolabi,1 Naheem Adekilekun Tijani,1 Yusuf Olusola Faseun,1 Martin Odoki,1 Christine Gechemba Mokaya,1 Danladi Makeri,1 Shango Patience Emmanuel Jakheng,1 Vidya Sankarapandian,1 ...
Hambali KU, Eilu E, Kumar S, Afolabi AO, Tijani NA, Faseun YO, Odoki M, Mokaya CG, Makeri D, Jakheng SPE, Sankarapandian V, Adeyemo RO, Adegboyega TT, Adebayo IA, Ntulume I, Akinola SA   +15 more
doaj  

Integrative genomic analysis reveals DHX58 as a key player in gastric cancer. [PDF]

PLoS One
Li Y, Zhang L, Wen Z, Wang H, Zhang K, Wang B, Li J, Kang H, Gao Y, Yu Z, Du Y.   +10 more
europepmc   +1 more source

Plants use identical inhibitors to protect their cell wall pectin against microbes and insects

, 2020
Eberl, F., Haeger, W., Kirsch, R., Pauchet, Y., Schaefer, C., Sporer, T., Vurmaz, E.   +6 more
core   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

The IGVF catalog-from genetic variation to function. [PDF]

Nucleic Acids Res
Li D, Liu S, Assis PR, Li M, Dong S, Whaling I, Jolanki O, Kagda M, Zhang W, Macias-Velasco JF, Liu T, Cody S, Antonacci-Fulton L, Huang Y, Liu J, Montgomery MT, Zeiberg D, Jain S, Pejaver V, Bergquist T, Chen Y, Radivojac P, Gersbach CA, Sherpa RN, Castro CP, Boyle AP, Starita LM, Fowler DM, Ahituv N, Dey KK, Majoros WH, Reddy TE, Craven M, Sinha R, Sverchkov Y, Cai X, Nzima MZ, Calderwood MA, Rozowsky J, Gerstein M, Ma J, Yue F, Cherry JM, Love MI, Engreitz JM, Hitz BC, Wang T.   +46 more
europepmc   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source